Ann: Nova Majority owned Snow Lake Resources Prices IPO, page-302

First 302 Last

Share
Profile

Follow
wot

10,327 Posts.

1463

22/11/21

14:15

Post #: 57755074
Share

Originally posted by thecrabpest: ↑

Hi Wot, just a small word of advice.

If you think the ASX is full of games and sharks, it pails in comparison to the US markets where there is way more money being deployed in both positive and negative ways.

Heck, there are people who make more in commission in 6 months than this company raised for it IPO.

Snow Lake has zero revenues, and is unlikely to have revenues for some time yet, so it will need to raise (and dilute) to achieve every milestone.

The company has set itself a high bar for the type of operation it wants to establish, which is on top of an already complicated process of building and optimising a mine.

Investors are forward looking and markets are cyclical, and whilst you may be willing to wait 5 years to get a return, unless the company has some sort of USP, I think many investors will put their money into opportunities that will offer higher returns on a shorter timeline.

Lithium is a commodity.

There are much bigger mines and operations out there that are making money right now, or are coming online in the next 12 months.

The technology around battery creation and recycling is evolving at a rapid pace, and who knows what that will look like in 5 years - which is likely to be the timeline before this goes into production.

Whilst demand is strong, there is a lot more production coming online within the next 5 years, which will take the pressure out of the market.

This is the second bull market for lithium in 5 years, and I think the company missed the second boat on this one in order to truly capitalise on the hype and opportunity.

Expand

Thanks for the advice. However I feel 300m is a reasonable market cap even at these early stages relative to comparable lithium stocks on the Nasdaq.

NVA Price at posting: 16.8¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

ASX Market Open: ASX200 to open weak on Wall Street losses, as US investors factor in a lower Fed rate cut next month | October 8, 2024

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 248 more messages in this thread...

First 302 Last

Add NVA (ASX) to my watchlist

(20min delay)
Last 16.5¢		Change 0.010(6.45%)		Mkt cap ! $44.86M

Open	High	Low	Value	Volume
16.0¢	16.5¢	15.8¢	$79.18K	492.9K

Buyers (Bids)

No.	Vol.	Price($)
1	34183	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	18380	2

View Market Depth

No.	Vol.	Price($)
1	34183	0.165
2	87305	0.155
5	219938	0.150
4	138799	0.145
5	120527	0.140

Price($)	Vol.	No.
0.170	18380	2
0.175	23857	3
0.180	117642	1
0.190	33340	2
0.195	20000	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

NVA (ASX) Chart

Ann: Nova Majority owned Snow Lake Resources Prices IPO, page-302

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

ASX Market Open: ASX200 to open weak on Wall Street losses, as US investors factor in a lower Fed rate cut next month | October 8, 2024

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Nova Majority owned Snow Lake Resources Prices IPO, page-302

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

ASX Market Open: ASX200 to open weak on Wall Street losses, as US investors factor in a lower Fed rate cut next month | October 8, 2024

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News